Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024.
新泽西州普林斯顿，2023 年 12 月 13 日（GLOBE NEWSWIRE）——Acasti Pharma Inc.（纳斯达克股票代码：ACST）（Acasti 或该公司）是一家推进 GTX-104 的后期生物制药公司，其新型尼莫地平静脉注射配方正在开发中，以满足一种罕见疾病，即动脉瘤性蛛网膜出血（aSaH）未得到满足的医疗需求，今天宣布，首席执行官普拉尚特·科利将在2024年1月7日至12日这一周参加在加利福尼亚州旧金山举行的以下投资者和行业社交活动。
译文内容由第三方软件翻译。